4.6 Review

The clinical spectrum of childhood narcolepsy

Journal

SLEEP MEDICINE REVIEWS
Volume 38, Issue -, Pages 70-85

Publisher

W B SAUNDERS CO LTD
DOI: 10.1016/j.smrv.2017.04.003

Keywords

Narcolepsy; Cataplexy; Movement disorder; Obesity; Precocious puberty; Treatment

Funding

  1. UCB pharma
  2. Jazz pharmaceuticals
  3. Theranexus
  4. Flamel
  5. Bioprojet

Ask authors/readers for more resources

Narcolepsy type 1 is a life-long, severe, multifaceted disease often arising in childhood or adolescence. Beyond the classical symptoms (excessive daytime sleepiness, cataplexy, hallucinations, sleep paralysis and nocturnal fragmented sleep), metabolic, endocrinological, psychiatric and psychosocial aspects must be considered. Despite the increased awareness after H1N1 pandemic influenza and vaccination, narcolepsy is still misdiagnosed and unrecognized. The peculiar presentation of symptoms in narcoleptic children could in part explain the misdiagnoses. Excessive daytime sleepiness presenting as chronic drowsiness or irritability could be stigmatized as laziness or misinterpreted as behavior or inattention disorder. The persistent hypotonia and the complex hyperkinetic movements that characterize cataplexy close to the onset, could be misdiagnosed as a movement disorder or as other neurologic conditions. The consequent therapeutic delay could turn into dramatic consequences. The narcolepsy onset, indeed, is associated with abrupt weight gain and sometimes with precocious puberty that require a prompt recognition and treatment to avoid auxological and metabolic complications. Moreover, narcoleptic children could have behavioral and psychiatric disorders ranging from mood to psychotic ones that need ad hoc management. Accordingly, spreading the awareness outside the sleep specialist community is necessary in order to reduce the diagnostic delay and to obtain prompt and multidisciplinary management. (C) 2017 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Evening-types show highest increase of sleep and mental health problems during the COVID-19 pandemic-multinational study on 19 267 adults

Ilona Merikanto, Laura Kortesoja, Christian Benedict, Frances Chung, Jonathan Cedernaes, Colin A. Espie, Charles M. Morin, Yves Dauvilliers, Markku Partinen, Luigi De Gennaro, Yun Kwok Wing, Ngan Yin Chan, Yuichi Inoue, Kentaro Matsui, Brigitte Holzinger, Giuseppe Plazzi, Sergio Arthuro Mota-Rolim, Damien Leger, Thomas Penzel, Bjorn Bjorvatn

Summary: During the COVID-19 pandemic, evening-types experienced poorer mental health, well-being, and quality of life compared to other circadian types. They also reported delayed sleep-wake schedules, increased sleep duration, and more severe sleep problems. Meanwhile, morning-types were less vulnerable to sleep changes and experienced protection from most sleep problems.

SLEEP (2022)

Article Neurosciences

Restless Legs Syndrome: Known Knowns and Known Unknowns

Elena Antelmi, Lorenzo Rocchi, Anna Latorre, Daniele Belvisi, Francesca Magrinelli, Kailash P. Bhatia, Michele Tinazzi

Summary: Although restless legs syndrome (RLS) is a common neurological disorder, it is poorly understood from a clinical and pathophysiological perspective. However, based on several lines of evidence, it is proposed that RLS should be seen as a disorder of sensorimotor interaction with a typical circadian pattern of occurrence.

BRAIN SCIENCES (2022)

Correction Clinical Neurology

Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications (vol 36, pg 633, 2022)

Yves Dauvilliers, Karel Sonka, Richard K. Bogan, Markku Partinen, Rafael Del Rio Villegas, Nancy Foldvary-Schaefer, Roman Skowronski, Abby Chen, Jed Black, Franck Skobieranda, Michael J. Thorpy

CNS DRUGS (2022)

Review Clinical Neurology

The orexin story, sleep and sleep disturbances

Fabio Pizza, Lucie Barateau, Yves Dauvilliers, Giuseppe Plazzi

Summary: The orexins, or hypocretins, are neuropeptides produced by neurons in the lateral hypothalamus and play a role in regulating sleep, wakefulness, and other functions. Destruction of orexin neurons leads to narcolepsy in humans, and impairments in orexin signaling cause narcoleptic-like symptoms in animals. The discovery of orexins has revolutionized sleep research and holds promise for therapeutic applications in various fields.

JOURNAL OF SLEEP RESEARCH (2022)

Article Clinical Neurology

Changes in Sleep Pattern During the COVID-19 Lockdown in Patients With Narcolepsy, Idiopathic Hypersomnia, and Restless Legs Syndrome

Lucie Barateau, Sofiene Chenini, Anna Laura Rassu, Claire Denis, Quentin Lorber, Cloe Dhalluin, Regis Lopez, Isabelle Jaussent, Severine Beziat, Yves Dauvilliers

Summary: During the COVID-19 lockdown, patients with narcolepsy and idiopathic hypersomnia extended their sleep duration, while patients with restless legs syndrome did not. These changes had negative consequences on their quality of life.

NEUROLOGY (2022)

Article Clinical Neurology

Sleep symptoms are essential features of long-COVID - Comparing healthy controls with COVID-19 cases of different severity in the international COVID sleep study (ICOSS-II)

Ilona Merikanto, Yves Dauvilliers, Frances Chung, Yun Kwok Wing, Luigi De Gennaro, Brigitte Holzinger, Bjorn Bjorvatn, Charles M. Morin, Thomas Penzel, Christian Benedict, Adrijana Koscec Bjelajac, Ngan Yin Chan, Colin A. Espie, Harald Hrubos-Strom, Yuichi Inoue, Maria Korman, Anne-Marie Landtblom, Damien Leger, Kentaro Matsui, Sergio Mota-Rolim, Michael R. Nadorff, Giuseppe Plazzi, Catia Reis, Juliana Yordanova, Markku Partinen

Summary: An international survey study reveals that post-acute sequelae of COVID-19 symptoms are more prevalent among severe cases and long-lasting sleep problems are at the core of these symptoms. Understanding the importance of sleep-related symptoms has clinical relevance in diagnosing and treating long-COVID.

JOURNAL OF SLEEP RESEARCH (2023)

Article Clinical Neurology

Home nocturnal infrared video to record non-rapid eye movement sleep parasomnias

Regis Lopez, Lucie Barateau, Sofiene Chenini, Anna Laura Rassu, Yves Dauvilliers

Summary: This study evaluated the feasibility, acceptability, and usefulness of home nocturnal infrared video recording in assessing the frequency and complexity of non-rapid eye movement sleep parasomnias in adults, as well as monitoring treatment response.

JOURNAL OF SLEEP RESEARCH (2023)

Article Clinical Neurology

Rapid eye movement sleep duration during the multiple sleep latency test to diagnose hypocretin-deficient narcolepsy

Regis Lopez, Lucie Barateau, Anna Laura Rassu, Elisa Evangelista, Sofiene Chenini, Sabine Scholz, Isabelle Jaussent, Yves Dauvilliers

Summary: The study aims to evaluate alternative measures of the multiple sleep latency test (MSLT) for identifying hypocretin-deficiency in patients with hypersomnolence, including narcolepsy patients. The results show that compared to the current neurophysiological standard criteria, alternative MSLT measures are more effective in identifying hypocretin-deficient patients with hypersomnolence and narcolepsy. Daytime REM sleep duration is highlighted as a relevant neurophysiological biomarker of hypocretin-deficiency, which can be used in clinical and research settings.

SLEEP (2023)

Article Medicine, General & Internal

Impact of Obstructive Sleep Apnea Syndrome on Ventricular Remodeling after Acute Myocardial Infarction: A Proof-of-Concept Study

Francois Bughin, Helene Kovacsik, Isabelle Jaussent, Kamila Solecki, Sylvain Aguilhon, Juliette Vanoverschelde, Hamid Zarqane, Jacques Mercier, Fares Gouzi, Francois Roubille, Yves Dauvilliers

Summary: This study aimed to investigate the impact of obstructive sleep apnea syndrome (OSA) on ventricular remodeling post-acute myocardial infarction (AMI). The results showed no association between OSA and ventricular remodeling in patients with moderate to severe AMI. These findings highlight the complexity of the relationship between OSA and post-AMI morbi-mortality.

JOURNAL OF CLINICAL MEDICINE (2022)

Article Clinical Neurology

Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder

Dieter Kunz, Yves Dauvilliers, Heike Benes, Diego Garcia-Borreguero, Giuseppe Plazzi, Dalma Seboek Kinter, Preciosa Coloma, Magdalene Rausch, Mouna Sassi-Sayadi, Stephen Thein

Summary: In this 40-week extension study, Daridorexant was found to be safe and well-tolerated for long-term treatment of insomnia disorder. It improved sleep and daytime functioning, with the most pronounced effects observed with the 50 mg dose.

CNS DRUGS (2023)

Article Clinical Neurology

Brain-derived neurotrophic factor (BDNF) variants and promoter I methylation are associated with prolonged nocturnal awakenings in older adults

Marie-Laure Ancelin, Isabelle Jaussent, Karen Ritchie, Alain Besset, Joanne Ryan, Yves Dauvilliers

Summary: This study examines the association between BDNF variants and promoter I methylation with sleep disturbances in older adults. The results show that wake time after sleep onset (WASO) is associated with four SNPs in participants not taking psychotropic drugs, while the associations are either not significant or in the reverse direction in participants taking drugs. Higher BDNF methylation levels are found in participants with long WASO, and this varies depending on psychotropic drug use.

JOURNAL OF SLEEP RESEARCH (2023)

Article Clinical Neurology

Cognitive strategies to improve symptoms of restless legs syndrome

Sofiene Chenini, Lucie Barateau, Lily Guiraud, Marie-Lou Rollin, Regis Lopez, Isabelle Jaussent, Severine Beziat, Yves Dauvilliers

Summary: One-third of patients with restless legs syndrome reported a decrease in symptoms during cognitive activities, and this improvement was confirmed during a sustained cognitive task.

JOURNAL OF SLEEP RESEARCH (2023)

Article Clinical Neurology

Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial

Yves Dauvilliers, Thomas Roth, Richard Bogan, Michael J. Thorpy, Anne Marie Morse, Asim Roy, Jordan Dubow, Jennifer Gudeman

Summary: This study evaluated the efficacy of extended-release once-nightly sodium oxybate (ON-SXB; FT218) compared to placebo for daytime sleepiness and disrupted nighttime sleep in narcolepsy type 1 (NT1) and 2 (NT2). The results showed significant improvements in sleep latency, sleep quality, nocturnal arousals, and daytime sleepiness for both NT1 and NT2 subgroups treated with ON-SXB compared to placebo.

SLEEP (2023)

Article Clinical Neurology

Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem

Tobias Di Marco, Thomas E. Scammell, Michael Meinel, Dalma Seboek Kinter, Alexandre N. Datta, Gary Zammit, Yves Dauvilliers

Summary: The study aimed to explore the effect of daridorexant, a dual orexin receptor antagonist, on nighttime wake bouts and their correlation with daytime functioning. Results showed that daridorexant reduced the number and duration of long wake bouts during the night compared with placebo, corresponding with improved daytime functioning.

CNS DRUGS (2023)

Review Immunology

The immunopathogenesis of narcolepsy type 1

Roland S. Liblau, Daniela Latorre, Birgitte R. Kornum, Yves Dauvilliers, Emmanuel J. Mignot

Summary: Narcolepsy type 1 (NT1) is a chronic sleep disorder caused by the loss of certain hypothalamic neurons. It is suspected to have an immune-mediated basis, supported by genetic evidence and increased incidence after vaccination. The search for antigens recognized by pathogenic T cell response in NT1 is ongoing, and animal models provide insights into the roles of autoreactive T cells.

NATURE REVIEWS IMMUNOLOGY (2023)

No Data Available